

Table 83. Vaccination coverage among adolescents 13–17 years of age for selected diseases, by selected characteristics: United States, 2006–2009

[Data are based on telephone interviews of a sample of the civilian noninstitutionalized population, supplemented by a survey of immunization providers for interview participants]

Vaccination coverage	2006 ¹	2007 ¹	2008	2009						
Percent of adolescents 13–17 years										
Measles, mumps, rubella (2 doses or more) . . .	86.9	88.9	89.3	89.1						
Hepatitis B (3 doses or more)	81.3	87.6	87.9	89.9						
History of varicella or received varicella vaccine (2 doses or more) ²	---	---	73.5	75.7						
Td or Tdap (1 dose or more) ³	60.1	72.3	72.2	76.2						
Tdap (1 dose or more) ³	10.8	30.4	40.8	55.6						
Meningococcal conjugate vaccine (MCV4) (1 dose or more) ⁴	11.7	32.4	41.8	53.6						
Quadrivalent human papillomavirus (HPV4) (1 dose or more) ⁵	---	25.1	37.2	44.3						
Quadrivalent human papillomavirus (HPV4) (3 doses or more) ⁵	---	---	17.9	26.7						
	<i>Race and Hispanic origin⁶</i>		<i>Poverty level⁷</i>		<i>Location of residence</i>					
	<i>Not Hispanic or Latino</i>				<i>Inside MSA⁸</i>					
	<i>American</i>		<i>At or</i>							
	<i>Black or</i>	<i>Indian or</i>	<i>Below</i>							
	<i>African</i>	<i>Alaska</i>	<i>poverty</i>							
	<i>White</i>	<i>Native</i>	<i>level</i>							
		<i>Asian</i>	<i>level</i>							
			<i>or</i>							
			<i>Latino</i>							
			<i>city</i>							
			<i>Remaining</i>							
			<i>area</i>							
			<i>Outside</i>							
			<i>MSA⁸</i>							
	Percent of adolescents 13–17 years									
Measles, mumps, rubella (2 doses or more) . . .	90.2	86.3	90.4	92.9	87.6	87.8	89.3	88.5	90.2	87.5
Hepatitis B (3 doses or more)	90.2	88.9	89.7	89.5	90.0	88.3	90.3	89.2	91.6	86.9
History of varicella or received varicella vaccine (2 doses or more) ²	77.0	71.3	71.9	72.6	74.9	74.4	75.9	---	---	---
Td or Tdap (1 dose or more) ³	76.5	72.5	78.0	84.5	76.7	71.8	77.0	79.7	77.3	64.4
Tdap (1 dose or more) ³	55.8	52.7	59.3	64.3	55.6	52.8	56.1	60.1	55.0	46.3
Meningococcal conjugate vaccine (MCV4) (1 dose or more) ⁴	53.1	53.0	46.9	58.8	55.9	52.5	53.8	58.3	55.9	36.0
Quadrivalent human papillomavirus (HPV4) (1 dose or more) ⁵	43.9	44.6	52.3	41.5	45.5	51.9	42.5	49.4	42.5	37.5
Quadrivalent human papillomavirus (HPV4) (3 doses or more) ⁵	29.1	23.1	29.6	22.1	23.4	25.5	26.8	---	---	---

--- Data not available.

¹For 2006 and 2007, data were only collected in the 4th quarter of the year. Starting with 2008, data were collected for the entire year.

²Varicella is chickenpox.

³Td or Tdap refers to tetanus toxoid-diphtheria vaccine (Td) or tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) received since the age of 10 years.

⁴Includes persons receiving MCV4 or meningococcal-unknown type vaccine.

⁵Percents reported among females.

⁶Persons of Hispanic origin may be of any race. Estimates were tabulated using the 1997 Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity. Data for Native Hawaiian and Other Pacific Islander persons and persons of multiple races were not included because of small sample sizes. See Appendix II, Hispanic origin; Race.

⁷Poverty level is based on family income and family size using U.S. Census Bureau poverty thresholds. In 2009, less than 1% (unweighted) of adolescents with provider-reported vaccination data were missing information about poverty level and were not included in the estimates of vaccination coverage by poverty level. See Appendix II, Poverty.

⁸MSA is metropolitan statistical area. See Appendix II, Metropolitan statistical area.

NOTES: Vaccination coverage estimates are based on provider-verified responses from parents who live in households with telephones. Complex statistical methods are used to adjust vaccination estimates to account for adolescents whose parents refuse to participate in the survey, for adolescents who live in households without telephones, or for adolescents whose vaccination histories cannot be verified through their providers. Detailed vaccination data among adolescents, by race and Hispanic origin, percent of poverty level, and MSA were not available prior to 2008. Interpretation of vaccination data needs to take into account when specific vaccines were licensed and recommended for use among adolescents. HPV4 vaccine was licensed by the U.S. Food and Drug Administration in June 2006. For the initial recommendations on HPV4 vaccination, see: CDC. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices. MMWR 2007;56(RR-02):1–24. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm?s_cid=rr5602a1_e. MCV4 vaccine was licensed for use by the U.S. Food and Drug Administration in January 2005. For the initial recommendations on MCV4 vaccination, see: CDC. Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices. MMWR 2005;54(RR-07):1–21. Available from: <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5407a1.htm>. Tdap vaccines were licensed by the U.S. Food and Drug Administration in May and June of 2005. For the initial recommendations on Tdap vaccination, see: CDC. Preventing tetanus, diphtheria, and pertussis among adolescents: Use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices. MMWR 2006;55(RR-03):1–34. Available from: <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5503a1.htm>. See Appendix I, National Immunization Survey. Additional information on the recommended schedule for adolescent vaccination is available from: <http://www.cdc.gov/vaccines/recs/schedules/child-schedule.htm#printable>.

SOURCE: CDC/NCHS and National Center for Immunization and Respiratory Diseases, National Immunization Survey. Available from: <http://www.cdc.gov/vaccines/stats-surv/imz-coverage.htm#nisteen>.